Polyols can be produced from a waste polyurethane product by exposing the waste polyurethane product to a vapor of a reagent and reacting to produce a reaction product comprising one or more polyols, one or more polyesters or both wherein the reagent comprises a carboxylic acid or an acid anhydride or a mixture thereof provided that wherein the reagent is an acid anhydride the reaction occurs in the presence of water.
C08J 11/14 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with steam or water
C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters
A working electrode for use with an electrochemical analyte recognition element-based sensor. The working electrode has associated analyte recognition elements specific for a target analyte. The recognition elements including a first population allowing for quantitation of the target analyte across a first concentration range, and a second population allowing for quantification of the target analyte across a second concentration range. The first and second concentration ranges are different.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
A cathode active material useful in an electrode and including a compound comprising a lithium transition metal oxide, a sodium transition metal oxide, a lithium transition metal oxyfluoride, or a sodium transition metal oxyfluoride. The compound has a cation disordered rocksalt (DRX) structure, and all of the cation sites of the DRX structure are occupied by a transition metal ion (M) that has one or more electrons in its d-shell. Further, the compound is comprised of large (micron-sized) particles.
H01M 50/40 - SeparatorsMembranesDiaphragmsSpacing elements inside cells
H01M 50/409 - Separators, membranes or diaphragms characterised by the material
H01M 50/489 - Separators, membranes, diaphragms or spacing elements inside the cells, characterised by their physical properties, e.g. swelling degree, hydrophilicity or shut down properties
4.
POLYQUBIT ENCODING FOR QUANTUM INFORMATION PROCESSING
Polyqubit encodings for quantum information processing are provided. In an exemplary embodiment, a plurality of quantum objects is provided. Each of the plurality of quantum objects has at least four states. The at least four states have a first partition and a second partition distinct from the first. The first partition corresponds to a first qubit and the second partition corresponds to a second qubit. The first qubit and the second qubits are separately manipulable. A first pair of transitions is driven across one of the first or the second partitions in a first of the plurality of quantum objects, thereby applying a gate to the corresponding qubit in the first of the plurality of quantum objects. Various embodiments enable intra-object gates and enable state preparation and measurement on qubits without affecting other qubits in the same quantum object.
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
Adoptive T-cell therapy has shown tantalizing promise as a cancer treatment strategy, with several clinical trials reporting that T cells expressing chimeric antigen receptors (CARs) can eradicate tumors in patients with relapsed disease. However, CAR-T cells rely on receptor-mediated recognition of surface-bound antigens that are seldom tumor-exclusive, resulting in severe on-target, off-tumor toxicities that have led to patient deaths in clinical trials. There is a growing consensus that the lack of suitable antigens poses a major obstacle to the broad application of engineered tumor-targeting T cells. The ability to overcome T cells' reliance on surface antigen presentation and interrogate intracellular disease signatures would significantly expand the pool of detectable tumor markers and improve tumor-targeting specificity. Here, we present a novel strategy to reprogram T-cell-mediated cytotoxicity to interrogate intracellular disease signatures. We have engineered a switchable form of the cytotoxic protein Granzyme B (GrB) that is produced and delivered by T cells into target cells, but becomes active if and only if a tumor-associated protease is present inside the target cell. As a proof of concept, we have developed a GrB switch that responds to Sentrin-specific protease 1 (SENP1), an oncoprotein known to be overexpressed in prostate, pancreatic, and thyroid oncocytic tumor cells. We demonstrate that this GrB switch, termed cytoplasmic oncoprotein verification evaluator and response trigger (COVERT), is efficiently expressed and packaged by human T cells and properly trafficked to the immunological synapse between T cells and target cells. Furthermore, we show that COVERT is produced as an enzymatically inert protein that is activated by SENP1 in a dose-dependent manner. Finally, we describe designs to adapt COVERT into a modular platform technology that will expand the repertoire of candidate target antigens. We envision that COVERT can be utilized in combination with existing CAR technology to improve the tumor-targeting precision of cell-based immunotherapy.
Adoptive T-cell therapy has shown tantalizing promise as a cancer treatment strategy, with several clinical trials reporting that T cells expressing chimeric antigen receptors (CARs) can eradicate tumors in patients with relapsed disease. However, CAR-T cells rely on receptor-mediated recognition of surface-bound antigens that are seldom tumor-exclusive, resulting in severe on-target, off-tumor toxicities that have led to patient deaths in clinical trials. There is a growing consensus that the lack of suitable antigens poses a major obstacle to the broad application of engineered tumor-targeting T cells. The ability to overcome T cells' reliance on surface antigen presentation and interrogate intracellular disease signatures would significantly expand the pool of detectable tumor markers and improve tumor-targeting specificity. Here, we present a novel strategy to reprogram T-cell-mediated cytotoxicity to interrogate intracellular disease signatures. We have engineered a switchable form of the cytotoxic protein Granzyme B (GrB) that is produced and delivered by T cells into target cells, but becomes active if and only if a tumor-associated protease is present inside the target cell. As a proof of concept, we have developed a GrB switch that responds to Sentrin-specific protease 1 (SENP1), an oncoprotein known to be overexpressed in prostate, pancreatic, and thyroid oncocytic tumor cells. We demonstrate that this GrB switch, termed cytoplasmic oncoprotein verification evaluator and response trigger (COVERT), is efficiently expressed and packaged by human T cells and properly trafficked to the immunological synapse between T cells and target cells. Furthermore, we show that COVERT is produced as an enzymatically inert protein that is activated by SENP1 in a dose-dependent manner. Finally, we describe designs to adapt COVERT into a modular platform technology that will expand the repertoire of candidate target antigens. We envision that COVERT can be utilized in combination with existing CAR technology to improve the tumor-targeting precision of cell-based immunotherapy.
Copyright ® American Institute of Chemical Engineers. All rights reserved.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
7.
IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDES
Described herein are compositions and methods for treating inflammatory arthritic conditions that are effective systemically without causing generalized immunosuppression when administered locally into an inflammatory arthritis-affected joint or a draining lymph node of the arthritis-affected joint of a patient.
Methods, systems, and devices are described for reconstructing spatially resolved electrical activity in the brain. In some example embodiments, EEG and MRI data are used to estimate volumetric distribution of electrostatic potential inside the MRI domain throughout the entire brain. Spatially and temporally varying field estimates can be generated using a brain wave model which is based on weakly evanescent transverse cortical wave propagation and constrained using the tissue properties gained from the MRI data. The disclosed techniques enable brain activity imaging with high spatial and temporal resolution, thereby providing a tool for assessing functional brain states and monitoring changes in those states in relation to various normal and pathological conditions.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Disclose are methods, compositions and kits for the determination of kidney function that provide an alternative to the standard-of-cure used for eGFR calculations. Described herein are methods for quantitative measurement of ADMA and hydration markers in a urine sample, and process used to transform the input of these methods into a measure of kidney function. The methods allow ADMA and other biomarkers to be detected in urine samples from a subject using a simple and inexpensive assay that can be easily performed noninvasively and only require urine samples for the prediction of kidney function.
Provided herein are biomarkers and methods for generating scores useful for assessing psoriatic arthritis (PsA) disease activity in subjects previously diagnosed with PsA. The invention also provides predictive model methods based on the biomarkers, as well as computer systems, software embodiments of the models for scoring and optionally classifying samples, and methods of recommending optimal therapeutic regimens.
G01N 33/531 - Production of immunochemical test materials
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
12.
APPLICATIONS AND IMAGING OF SHEAR-THINNING BIOMATERIAL
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
The Regents of the University of California (USA)
Boston Scientific Scimed, Inc. (USA)
Inventor
Oklu, Rahmi
Albadawi, Hassan
Sheikhi, Amir
Khademhosseini, Ali
Jabbarzadeh, Ehsan
Abstract
Systems and methods of using and imaging shear-thinning biomaterial compositions are provided. More particularly, systems and methods of providing reversible birth control and/or for delivering therapeutics to reproductive organs are provided. A method includes administering a biomaterial into fallopian tubes, uterus, or vas deferens of the subject, where the biomaterial is a shear-thinning nanocomposite.
The present disclosure relates to methods and tools for enhancing cognition and improving well being in an individual. The methods involve presenting to an individual a task to be performed, presenting to the individual an interference, and receiving inputs from the individual. Where the interference is a distraction, the individual is to ignore the interference. Where the interference is an interruptor, the individual is instructed to respond to the interruptor as a secondary task and is said to be multi-tasking. Inputs are then also received from the individual pertaining to this secondary task. The methods encompass iterations of these presentating steps and receiving of the input, and generation of analysis and/or feedback to the individual. The methods can further include conducting an analysis and/or generating feedback to the individual. The analysis can include a comparison of the performances with or without each type of interference.
G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
H04L 67/10 - Protocols in which an application is distributed across nodes in the network
14.
METHODS FOR SCAR REDUCTION BY CONVERTING SCAR FIBROBLASTS INTO ADIPOCYTES WITH HAIR FOLLICLE-DERIVED SIGNALS
The Trustees of the University of Pennsylvania (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Cotsarelis, George
Guerrero-Juarez, Christian F.
Plikus, Maksim
Abstract
This invention describes methods for treating wound healing pathologies, inhibiting or reversing fibrotic skin disorders, including but not limited to keloids, atrophic and hypertrophic scars, and reversing skin aging via generating new dermal adipocytes (DAs). Methods described herein comprise (a) grafting of human hair follicles or (b) direct delivery of conditioned media from in vitro cultured hair follicles, or (c) delivery of purified individual factors secreted by hair follicles, or (d) delivery of small molecule agonists that mimic hair derived signaling activities, or (e) delivery of small molecule antagonists that inhibit anti-adipogenic programs, or (f) delivery of small molecule agonists of pro-adipogenic programs to convert endogenous wound or scar skin fibroblasts into new DAs.
Materials comprising a protective coating for thermal protection are disclosed herein. The protective coating is comprised of a sacrificial layer, sacrificial component, or an intumescent layer organized in diverse geometries bioinspired from the thermal resistant structures in pyrophytic plants from the Banksia genus. The protective coating can be applied to various substrates and used for thermal management, water rescue, or crash safety.
A device receives a real image (e.g., photograph or video frame) that includes a human. The device creates a synthetic image corresponding to the real image. The synthetic image includes a synthetic environment and a humanoid shape that correspond to the human. The device predicts, using a trained viewpoint neural network and based on the synthetic image, a predicted viewpoint heatmap. The device predicts, using a trained pose neural network and based on the synthetic image, a predicted pose heatmap. The device provides, as input to a random synthetic environment, the predicted viewpoint heatmap and the predicted pose heatmap and creates a reconstructed three-dimensional pose based on the predicted viewpoint heatmap, the predicted pose heatmap, and the random synthetic environment. The device classifies the reconstructed three-dimensional pose as a particular type of pose of the human in the real image.
Provided herein are engineered linear RNA polynucleotide molecules that form circular RNA polynucleotide molecules in cells. Also provided are DNA constructs encoding the engineered linear RNA polynucleotide molecules.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
18.
HUMAN T CELL RECEPTOR PAIRS REACTIVE WITH HLA-A*02:01 RESTRICTED HUMAN PROSTATIC ACID PHOSPHATASE (PAP) EPITOPES
Aspects of the present disclosure relate to methods and compositions related to related to the preparation of immune cells, including engineered T cells having T cell receptors that target human prostatic acid phosphatase (PAP) and are useful in prostate cancer therapy.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The disclosure provides for compounds and compositions comprising hydrophilic-masked cationic charge dendrimers, and applications thereof, including delivering siRNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vectors. The methods and approaches disclosed herein can also be applied to lipids to make hydrophilic-masked cationic charge lipid nanoparticles for mRNA, RNA, siRNA, DNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vector delivery.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
21.
ULTRA-CLEAN VAN DER WAALS HETEROSTRUCTURES AND TECHNIQUES OF FABRICATION THEREOF
Disclosed are heterostructures that deploy one or more ultra-clean layers of van der Waals materials (VdW heterostructures). Further disclosed are techniques of fabricating VdW heterostructures that include patterning a conducting layer positioned on a substrate, separating, using a curved lifting surface, the patterned conducting layer from the substrate, and transferring the patterned conducting layer to a receiving stack of one or more layers while removing residual contaminants.
H10D 62/80 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials
H10D 62/85 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group III-V materials, e.g. GaAs
22.
DTC LINEARIZATION VIA MISMATCH-NOISE CANCELLATION FOR DIGITAL FRACTIONAL-N PLLS
A fractional-N PLL includes a reference oscillator, a multi-modulus divider-based phase-error-to-digital converter driven by the reference oscillator, a digital loop filter, and a digitally controlled oscillator. Digital-to-time to converter mismatch noise cancellation digital logic is between the phase-error-to-digital converter and the digital loop filter. Error from digital-to-time converter component mismatches is partially cancelled by the digital logic.
Process and device configurations are provided for prioritized inertial measurement unit (IMU) position tracking. In one embodiment, a method is provided including receiving sensor output for a plurality of inertial measurement unit (IMU) sensors, and generating a measurement vector for output of the plurality of IMU sensors. The method can also include selecting sensor output of a first IMU sensor, wherein the sensor output for the first IMU sensor is selected using noise performance of sensor output for the first IMU sensor. The method can also include outputting a measurement vector of the first IMU sensor.
G01C 21/16 - NavigationNavigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigatedDead reckoning by integrating acceleration or speed, i.e. inertial navigation
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
24.
SYSTEMS AND METHODS FOR A HIGH-SENSITIVE OSCILLATOR
Some embodiments relate to systems and methods for electronic circuits configured to operate at or near an exceptional point of degeneracy (EPD). An electronic system includes an electronic circuit configured to operate approximately at an EPD. The electronic circuit includes an active component that, via an instability, brings the system to self-oscillations, wherein a second component of the circuit is perturbed leading to high sensitivity to such perturbation.
H03B 5/02 - Generation of oscillations using amplifier with regenerative feedback from output to input Details
H03B 5/12 - Generation of oscillations using amplifier with regenerative feedback from output to input with frequency-determining element comprising lumped inductance and capacitance active element in amplifier being semiconductor device
H03B 5/18 - Generation of oscillations using amplifier with regenerative feedback from output to input with frequency-determining element comprising distributed inductance and capacitance
25.
PARTICLE-DROP STRUCTURES AND METHODS FOR MAKING AND USING THE SAME
Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and/or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and/or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.
A neuromodulation system, device, and method are disclosed. In an embodiment, a neuromodulation system includes a processor, a signal generator, a first electrode, and a second electrode. The processor in cooperation with the signal generator, the first electrode, and the second electrode are configured to deliver a transcutaneous stimulation to a user. The transcutaneous stimulation is configured by the processor for inducing voluntary movement in the user. The first electrode is positioned transcutaneously on the user's neck and the second electrode is positioned below the spinal cord injury. Additionally, the second electrode is laterally offset from the first electrode, on or over at least one of the spinal cord and/or spinal cord dorsal roots, a muscle, or a nerve.
Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and/or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and/or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity assays.
A method for determining the concentration of a target analyte in a sample including interrogating an electrochemical sensor with a potential waveform at a first frequency to provide a first current output value and at a second frequency to provide a second current output value. A mathematical relationship between the first and second current output values is used to determine a concentration value for the target analyte.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
purApurA gene encoding adenylosuccinate synthetase, wherein the variant Listeria bacteria are adenosine auxotrophs. The present disclosure provides compositions comprising a subject variant Listeria bacterium, including compositions further comprising a multispecific antibody. Also provided are immunogenic compositions comprising a variant Listeria bacterium of the present disclosure and kits comprising a unit dose thereof. The present disclosure additionally provides methods of inducing an immune response in an individual, the methods comprising administering to the individual an effective amount of an immunogenic composition of the present disclosure.
26655Cl (LPSC) solid electrolytes, which increases the effective electrochemical and chemical stability window of the electrolyte of lithium-based solid-state batteries, and enables stable cycling with a high voltage cathode and a metallic anode, with the potential to greatly enhance solid-state battery energy density.
H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
Medical images are reconstructed based on pixel intensity value groupings, which enables improved disease detection. Statistically significant pixels are identified from the medical images. These statistically significant pixels are grouped and the distributions of these pixels can be quantitatively characterized or otherwise analyzed to indicate potential clinical pathology in the subject.
A vascular access device includes a base housing and a needle guide extending from the base housing at an acute angle. The vascular access device also includes an acoustic sensor disposed in the base housing and configured to output a detection signal in response to detecting an acoustic signal generated by a blood vessel. The vascular access device further includes an indicator coupled to the acoustic sensor and configured to output an indication based on the detection signal.
The present disclosure provides antigen-binding proteins which bind to P2RY8, bispecific antigen-binding proteins which bind to P2RY8 and a second antigen, and conjugates thereof. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
34.
INHALED HYPOXIA AND SMALL MOLECULE FORMS OF HYPOXIA AS NOVEL ANTICANCER AGENTS
THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Midha, Ayush
Choi, Man Hung
Chew, Brandon Tamotsu Laijung
Jain, Isha H.
Goodarzi, Hani
Abstract
Provided herein are compositions and method to treat cancer comprising administering to subject in need thereof an agent, such as a small molecule to induce systemic hypoxia, having the subject breathe hypoxic air or a combination thereof.
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
New derivatives of human milk oligosaccharides and methods for preparing them are disclosed. Also described herein are hST6GALNAC V and hGCNT2-B variants, along with polynucleotides encoding the variants and host cells comprising the polynucleotides. Further provided herein are reaction mixtures comprising the hST6GALNAC V and hGCNT2-B variants.
The present disclosure provides materials and methods for identifying biomolecules from single cells and binding partners of the biomolecules using barcoded substrates such as beads. Provided herein are methods that enable generation of hundreds to billions of different molecular binders and simultaneous tagging with a molecular beacons are provided. The methods provided herein allow quick assembly of molecular probe libraries which can be used, in various embodiments, for highly multiplexed identification of molecular signatures and corresponding binder pairs.
Systems. materials. and methods for heat management and protecting a manufactured article or surface from thermal damage. The protective materials have heat absorbing elements comprised of a metastable or a thermally stable material. The materials include particles with high thermal conductivity. thermally conductive protrusions or patterns. heat absorbing matrices or layers, or a combination thereof. The materials can be applied to an article to prevent or reduce thermal damage.
A framework for generating a large-scale or unbound graphics design system file is disclosed. In one example aspect, the framework comprises receiving a target layout of the GDSII file, wherein the target layout includes multiple unit cells that each have a geometric shape and oriented at an angle. Upon receiving the target layout, the target layout is divided into blocks of equal size. Within each block, a position, rotation, and scaling of the geometric shapes is calculated. The shapes are generated within each block using matrix multiplication of transformation matrix and unit cell vectors, and the shapes are converted into a GDSII file format.
Process and device configurations are provided for prioritized inertial measurement unit (IMU) position tracking. In one embodiment, a method is provided including receiving sensor output for a plurality of inertial measurement unit (IMU) sensors, and generating a measurement vector for output of the plurality of IMU sensors. The method can also include selecting sensor output of a first IMU sensor, wherein the sensor output for the first IMU sensor is selected using noise performance of sensor output for the first IMU sensor. The method can also include outputting a measurement vector of the first IMU sensor.
G01C 21/16 - NavigationNavigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigatedDead reckoning by integrating acceleration or speed, i.e. inertial navigation
40.
RECEIVER ARCHITECTURE DEMODULATING 4N-QAM DIRECTLY IN ANALOG DOMAIN WITHOUT ANALOG-TO-DIGITAL CONVERTER (ADC)
Disclosed are example embodiments of a receiver. The receiver including a front-end amplification and filtering block configured to amplify a received signal and filter out a potential jammer signal from a communication channel. The receiver also including a quadrature mixer, coupled to the front-end amplification and filtering block, and configured to down-convert the amplified and filtered signal to baseband to generate a quadrature LO signal. Additionally, the receiver including a carrier synchronization loop configured to synchronize the quadrature LO signal and carrier phase of the received signal. The receiver also including a demodulator coupled to the quadrature mixer and the carrier synchronization loop.
Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
42.
MIXED SOLID-STATE IONIC-ELECTRONIC POLYMER CONDUCTORS FOR ELECTROCHEMICAL DEVICES
The present invention provides for a composition comprising: a solvent, optionally one or more active material and/or additive particles, and the conductive polymer of the present invention. In some embodiments, the composition is a slurry. The present invention also provides for a device comprising a current collector applied or coated with the composition of the present invention, and a method to convert a conductive polymer into a final form comprising: (a) providing a device of the present invention comprising a current collector applied or coated with the composition of the present invention; (b) thermally or optically treating the composition such that the conductive polymer is converted into a final form.
The disclosure provides for a combination therapy comprising different classes of medications for the treatment of tinnitus and other medical conditions, and methods of treatment thereof.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
The present disclosure provides antibodies that specifically bind to cyclic STAT-3 decoy oligonucleotide (CS3D). The antibodies and derivatives thereof that specifically bind to CS3D can be used in methods, such as, methods for determining pharmacokinetics of CS3D in a subject, e.g., a human receiving treatment with CS3D.
A surface electrode array device, resting state immune response prediction systems, and a method for predicting immune responses are disclosed. The surface electrode array device is configured to detect multi-channel cervical neuronal activity of a subject via several wearable sensors applied to the subject. The system includes a computing device with a receiving unit to receive sensor signals from several wearable sensors worn by a subject, a memory in which to load a resting state immune response prediction program, and a processor that performs operations of the program to determine immune response of the subject before the subject is symptomatic. The method includes receiving sensor signals from wearable sensors of a sensor array worn by a subject, classifying an inflammation risk for the subject based on the sensor signals, classifying an inflammation biotype for the subject based on the sensor signals, and creating a notification based on the results.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Hydrogel compositions are described with dynamic and tunable properties, mimicking extracellular matrix, for use in enhancing tissue remodeling, tissue engineering or wound healing, among others.
A Hybrid Switched Capacitor Converter (HSCC) topology is presented that is suitable for high conversion ratio Point-of-Load (PoL) applications. The topology specifically targets 48V to 1V power delivery in space-based high-performance computing systems, where size and weight are important considerations, along with device de-rating for radiation tolerance. One implementation merges an initial 2:1 switched capacitor conversion stage with a symmetric dual inductor hybrid (SDIH) conversion stage, reaping benefits of both. The SDIH stage offers reduced component count and an excellent switch stress figure of merit, while the initial 2:1 voltage reduction stage significantly reduces the volume of flying capacitors, enabling compact size and low weight.
H02M 3/07 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using resistors or capacitors, e.g. potential divider using capacitors charged and discharged alternately by semiconductor devices with control electrode
H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
50.
SYSTEMS AND METHODS FOR HIGH-THROUGHPUT, MULTI-WELL SPATIOTEMPORAL ILLUMINATION MICROSCOPY
A spatiotemporal illumination microscope system is presented. The system includes a multi-well plate configured to receive live cells and a DMD configured to deliver targeted illumination to selectively illuminate a plurality of the wells. The system further includes a tandem-lens system having an objective lens and an imaging lens positioned facing each other to capture fluorescent light emitted from the cells. The system also includes an image sensor that receives fluorescent light captured by the tandem-lens system, generating imaging data. The system further includes a controller configured to use the imaging data to control closed-loop modulation of the live cells.
A method for generating a radiation therapy treatment plan with breath hold for a subject includes receiving a plurality of free-breathing CT scans of the subject acquired with a CT imaging system, receiving breathing surrogate data for the subject, selecting a reference CT scan from the plurality of free-breathing CT scans, determining a breathing motion model with a breath hold component based on at least the plurality of free-breathing CT scans of the subject, the breathing surrogate data, and the reference CT scan, where the breathing motion model with a breath hold component is associated with the subject, and determining a breath hold position of a target tissue at a predetermined breathing amplitude using the breathing motion model with a breath hold component.
21 - HouseHold or kitchen utensils, containers and materials; glassware; porcelain; earthenware
41 - Education, entertainment, sporting and cultural services
Goods & Services
Cloth banners; cloth pennants Clothing, namely, tops, bottoms, shirts, t-shirts, polo shirts, sports shirts, sweatpants, sweatshirts, hoodies, jackets; headwear, namely, hats Beverage glassware; coffee cups; travel mugs; mugs; water bottles sold empty Educational services, namely, conducting classes, conferences, seminars, exhibitions and workshops at the undergraduate, graduate, university, doctorate and professional levels in the fields of art, sciences, humanities, photography, music, business, ecology, economics, education, engineering, defense technology, English language studies, foreign languages, healthcare and behavioral sciences, humanities and writing, information technology and software engineering, law, leadership and management development, life sciences, occupational and environmental safety and health, medicine, nursing, public service and social responsibility, government; educational seminars in the fields of anthropology, astronomy and astrophysics, bioengineering, Chicanx and Latinx studies, cinematic arts and film studies, computer science and engineering, history, literature, mathematics, mechanical and aerospace engineering, physics, political science, oceanography, visual arts; arranging and conducting visual, literary and performing arts presentations, namely, presentations of live show performances, musical performances, dance and ballet performances, theater productions and live literary readings and lectures; arranging and conducting collegiate and youth athletic and sporting events and competitions; providing information in the field of athletic competitions, namely, baseball and softball, basketball, crew, cross country, field hockey, football, fencing, golf, gymnastics, lacrosse, rugby, sailing, soccer, swimming and diving, tennis, track and field, volleyball, and water polo
54.
TIMO: TIME INTERLEAVED MULTIPLE OUTPUTS FOR ENABLING MULTIPLEXING GAINS WITH A SINGLE RF CHAIN
In some embodiments, there may be provided systems, methods, and articles of manufacture for timeinterleaved multiple output. In some example embodiments, there may be provided an apparatus including a plurality of antennas; an analog spreader coupled the plurality of antennas; a radio frequency chain coupled to the analog spreader, wherein the radio frequency chain down converts and performs an analog-to-digital conversion to generate a stream; and a digital despreader, wherein the digital despreader receives the stream output by the radio frequency chain and digitally inverts analog spreading caused by the analog spreader to generate one or more user streams. Related systems, methods, and articles of manufacture are also disclosed.
H04B 1/00 - Details of transmission systems, not covered by a single one of groups Details of transmission systems not characterised by the medium used for transmission
H04B 7/08 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the receiving station
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
56.
APPARATUS AND METHODS FOR LITHIUM, CALCIUM, AND MAGNESIUM EXTRACTION
Provided herein are assemblies and methods for lithium, magnesium, and/or calcium extraction. In various embodiments, an assembly includes a leaching tank defining an interior chamber having one or more inlets and one or more outlets. The leaching tank is configured to receive through the one or more inlets a mixture comprising a substrate having one or more target metals and a solvent. The assembly further includes a sonic probe positioned within the interior chamber, suspended in the solution, and/or a sonic plate configured to provide sonic energy to the mixture.
A system and method for monitoring medication intake uses vibration signals generated by a kinetic augmentation attachment. The attachment includes a base coupled to a medication container, a spring, and a weight, which produces distinct vibration signatures when the container is placed on a surface. A vibration sensor detects these signals, and a computing device processes them to extract features of the attachment and identify the medication container. The system does not require batteries, enabling long-term, maintenance-free monitoring. The method includes processing vibration signals using frequency analysis and machine learning to recognize different medication containers based on their kinetic signatures.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
The current disclosure is centered on the hypothesis that a better understanding of the neuroendocrine transdifferentiation (NEtD) process will provide therapeutic targets for inhibiting this transition and thus improving standard of care therapies. Accordingly, the current disclosure provides for a method for treating cancer in a subject, the method comprising administering an inhibitor of a gene, wherein the gene comprises one or more of tenascin C (TNC), advillin (AVIL), S100A7, PPARG, LOX lysyl oxidase, KLF5, APOBEC2, FOSL1, FOXM1, hedgehog, RELA, p65, IKK complex, JAK, STAT, TFAP4, geminin, OCA-1, OCA-2, Nf-kB, Nf-kB family and associated regulators, angiogenesis regulators such as BMX kinase, TEK kinase, periostin (POSTN), and VEGF family, stress genes, such as the JUN/FOS family, a gene from the S100 family, and cell state regulators such as ASCL1, POU2F3, NEUROD1, ASCL2, and YAP1.
Metal organic framework FexZn5-x(O2CC(O)R)4(btdd)3 for hydrocarbon oxygenation where R is an alkyl or aryl substituent compositions as illustrated with FexZn5-x(prv)4(btdd)3 where (x=1.0 to 1.8) and FeZn4(moba)4(btdd)3, are provided. High-spin Fe(IV)=O species are generated using O2 in a synthetic system that mimics α-ketoglutarate-dependent dioxygenases. Dioxygen activation yields a synthetic material capable of hydrocarbon oxidation catalysis at ambient temperatures via a high-spin iron(IV)-oxo intermediate. In the presence of O2, the frameworks are capable of catalytic oxygenation of cyclohexane and the stoichiometric conversion of ethane to ethanol and methane to methanol at ambient temperatures, for example. The frameworks allow for the catalytic oxygenation of a variety of hydrocarbons and conversions to alcohols.
C07C 45/33 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties
60.
SYSTEM AND METHOD FOR DEFORMING AND ANALYZING PARTICLES
A system for deforming a plurality of particles carried in a sample volume includes a reusable substrate defining an inlet, configured to receive the sample volume, and an outlet, wherein the inlet or outlet is configured to couple to a module to introduce or collect a washing or flushing solution. A fluidic pathway is disposed in the reusable substrate and fluidically couples to the inlet and the outlet and includes a delivery region fluidically coupled to the inlet and configured to focus the plurality of particles along at least one streamline and a deformation region located downstream with respect to the delivery region and formed by an intersection of the fluidic pathway and an opposing inlet channel, wherein flow of a fluid from the opposing inlet channel at the intersection mechanically deforms the plurality of particles passing through the deformation region.
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
A handheld, conforming capacitive sensing apparatus configured to measure Sub-Epidermal Moisture (SEM) as a mean to detect and monitor the formation of pressure ulcers. The device incorporates an array of electrodes which are excited to measure and scan SEM in a programmable and multiplexed manner by a battery-less RF-powered chip. The scanning operation is initiated by an interrogator which excites a coil embedded in the apparatus and provides the needed energy burst to support the scanning/reading operation. Each electrode measures the equivalent sub-epidermal capacitance corresponding and representing the moisture content.
The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
63.
ADAPTIVE DEEP BRAIN STIMULATION FOR SLEEP STAGE TARGETING TO TREAT SLEEP DYSFUNCTION
Devices, systems, software, and methods are provided for treating sleep dysfunction in a subject using nighttime deep brain stimulation. Deep brain stimulation is performed with a neural recording device that records brain electrical signal data while the subject is sleeping. Machine learning computational models are used to detect and classify patterns of neural activity associated with different sleep features or sleep stages. An adaptive deep brain stimulation algorithm is provided that modulates stimulation parameters using intracranially classified sleep features or sleep stages to target sleep dysfunction. Methods and systems are also provided for performing closed-loop therapy with a deep brain stimulator that records brain electrical signals from subcortical or cortical neural activity associated with selected sleep features or stages and automatically adjusts deep brain stimulator settings and/or delivers deep brain electrical stimulation when pre-specified patterns of neural activity associated with a selected sleep feature or sleep stage are detected.
The invention provides a method for removing perchlorate from an aqueous solution with a catalyst that comprises ruthenium in the presence of a nitrogen source or that comprises ruthenium on a nitrogen-functionalized support material. The invention also provides solutions and reactors that are useful for removing perchlorate from an aqueous solution.
The invention provides a catalyst comprising nickel (0) and one or more ligands that allow for electron reversibility. The catalysts are reactive in situ, but show tolerance to air, various solvents (including water), and a range of temperatures. The catalysts are useful to carry out coupling reactions (e.g., Kumada-Corriu coupling reactions).
A diffractive wavefront processor approximates the all-optical phase conjugation (OPC) operation for input fields with phase aberrations. A set of passive diffractive layers was optimized to all-optically process an arbitrary phase-aberrated input field, producing an output field with a phase distribution that is the conjugate of the input wave. Operation of the wavefront processor was experimentally validated by using fabricated diffractive layers trained using deep learning and performing OPC on phase distortions never seen during training. The diffractive wavefront processor successfully performed the OPC task through a shallow volume that axially spans tens of wavelengths. A diffractive phase-conjugate mirror was also created by combining deep learning-optimized diffractive layers with a standard mirror. The diffractive wavefront processor can be used for diverse OPC-related applications, e.g., turbidity suppression and aberration correction, and is also adaptable to different spectral bands of the electromagnetic spectrum.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means
Described herein is a robotic system configured for ophthalmic surgery, including: one or more articulated multi degree-of-freedom robotic linkage arms having at least a first and second joint and an end effector with a tool holder plate and tool driver, a stage configured for translation along XYZ planes of the one or more articulated multi-degree of freedom linkage arms, a surgical tool holder configured to receive one or more surgical tools, and a tool holder interface adapted and configured to engage with the surgical tool holder and the tool holder plate, wherein when the tool holder interface is coupled to the tool holder plate, the tool driver imparts motion to the one or more surgical tools within the surgical tool holder. Other examples are described.
Recombinant bacteriophages comprising a targeting moiety to a pathogen or pathological cell and also comprising a bioactive moiety effective against the pathogen or pathological cell are described that are useful for treating diseases such as infections and cancer. Such recombinant bacteriophages have a binding moiety to a pathogen or pathogenic cell expressed on a minor capsid protein, and a bioactive agent that is active against the pathogen or pathogenic cell bound to a major capsid protein.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Esanov, Rustam
Yang, Yeqing Angela
Sevim, Volkan
Shevade, Kaivalya
Przybyla, Laralynne
Shafer, Shawn
Abstract
Methods and compositions are provided for producing a smooth muscle cell (SMC) from a pluripotent stem cell, e.g., an induced pluripotent stem cell (iPSC), via MEOX1 overexpression. MEOX1 expression can be induced using any convenient method, e.g., by introducing an exogenous nucleic acid encoding MEOX1 or by using a tool such as CRISPRa to stimulate expression from the MEOX1 endogenous locus.
The present disclosure relates generally to detection on non-coding RNA molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
71.
WALL MOTION ABNORMALITY DETECTION VIA AUTOMATED EVALUATION OF VOLUME RENDERING MOVIES
Systems and methods that pertain to a cardiac function abnormality detection via automated evaluation of volume rendering movies are disclosed. In some implementations, a system includes a view generator to create a plurality of volume rendered views of an organ of a patient, a motion detector coupled to the view generator to detect a regional motion of a section of the organ based on the plurality of volume rendered views of the organ, and a display coupled to the motion detector to show the plurality of volume rendered views or a detection of an abnormality of the section.
A61B 6/46 - Arrangements for interfacing with the operator or the patient
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
72.
NOVEL LIVE MULTI-ANTIGENIC RECOMBINANT VACCINE AGAINST TUBERCULOSIS
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.
Natural killer (NK) cells are innate lymphocytes with cancer and viral immunosurveillance capabilities. Prior studies have established that human and mouse NK cells can acquire features of adaptive immunity, demonstrating immunological memory-like properties. Memory-like NK cells have been described in response to infection with cytomegalovirus in humans and mice, representing antigen-specific memory NK cells. NK cells, designated as cytokine-induced memory-like NK cells, with adaptive immune cell features can be generated in vitro and used in clinical trials in human cancer patients. Chimeric transmembrane receptor polypeptides expressed in natural killer cells or T-cells, are provided.
Metagenomics, metatranscriptomics and/or metatranslatomics measurement of the translational efficiency (TE) on genes and metabolic pathways using genome annotation, transcription and translation information of one or more identified member of a microbial consortia for the design and intervention of the microbial consortia. Also provided is the method for predicting the effect of perturbations on one or more members of a microbial consortia and a method for selecting one or more members of a microbial consortia for a particular task.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
75.
Methods and Compositions for Evaluating Biomarkers in Salivary Exosomes and Evaluating Cognitive Fatigue
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
John, Varghese
Teter, Bruce
Johnson-Cohn, Samuel Whitaker
Abstract
Disclosed herein are methods and compositions for diagnosing cognitive fatigue. Specifically, the disclosure provides a method of diagnosing a subject as suffering from cognitive fatigue, which comprises measuring the amount of a biomarker, comprising phosphoglycerate kinase 1 (PGK1) and/or miR3185, in an exosome sample obtained from a saliva sample from the subject, comparing the amount with a control, and identifying the subject as suffering from cognitive fatigue.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A method, a system, and computer program product for optical systems including a metasurface that supports quantitative phase imaging are provided. Optical system characteristics of an optical system are received. The optical system characteristics include an optical path, the optical system comprising a light source and an imaging system. Optical parameters of at least one metasurface are received. A location of the metasurface is selected within the optical path of the optical system to modulate an incident wavefront generated by the light source. An image acquired by the imaging system is processed, based on the optical parameters of the at least one metasurface and based on the location of the metasurface within the optical path, to determine one or more image properties.
Apparatus and methods for fluorescence imaging using radiofrequency multiplexed excitation. One apparatus splits an excitation laser beam into two arms of a Mach-Zehnder interferometer. The light in the first beam is frequency shifted by an acousto-optic deflector, which is driven by a phase-engineered radiofrequency comb designed to minimize peak-to-average power ratio. This RF comb generates multiple deflected optical beams possessing a range of output angles and frequency shifts. The second beam is shifted in frequency using an acousto-optic frequency shifter. After combining at a second beam splitter, the two beams are focused to a line on the sample using a conventional laser scanning microscope lens system. The acousto-optic deflectors frequency-encode the simultaneous excitation of an entire row of pixels, which enables detection and de-multiplexing of fluorescence images using a single photomultiplier tube and digital phase-coherent signal recovery techniques.
G02F 1/11 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on acousto-optical elements, e.g. using variable diffraction by sound or like mechanical waves
78.
METHOD AND DEVICE FOR HIGH THROUGHPUT CELL DEFORMABILITY MEASUREMENTS
A system is disclosed that enables the automated measurement of cellular mechanical parameters at high throughputs. The microfluidic device uses intersecting flows to create an extensional flow region where the cells undergo controlled stretching. Cells are focused into streamlines prior to entering the extensional flow region. In the extensional region, each cell's deformation is measured with an imaging device. Automated image analysis extracts a range of independent biomechanical parameters from the images. These may include cell size, deformability, and circularity. The single cell data that is obtained may then be used to in a variety of ways. Scatter density plots of deformability and circularity may be developed and displayed for the user. Mechanical parameters such as deformability and circularity may be gated or thresholded to identify certain cells of interest or sub-populations of interest. Similarly, the mechanical data obtained using the device may be used as cell signatures.
G01N 15/1433 - Signal processing using image recognition
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
A system is disclosed that enables the automated measurement of cellular mechanical parameters at high throughputs. The microfluidic device uses intersecting flows to create an extensional flow region where the cells undergo controlled stretching. Cells are focused into streamlines prior to entering the extensional flow region. In the extensional region, each cell's deformation is measured with an imaging device. Automated image analysis extracts a range of independent biomechanical parameters from the images. These may include cell size, deformability, and circularity. The single cell data that is obtained may then be used to in a variety of ways. Scatter density plots of deformability and circularity may be developed and displayed for the user. Mechanical parameters such as deformability and circularity may be gated or thresholded to identify certain cells of interest or sub-populations of interest. Similarly, the mechanical data obtained using the device may be used as cell signatures.
G01N 15/1433 - Signal processing using image recognition
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
A method for probing conformational dynamics is provided. The method comprises obtaining scattered photons by illuminating a sample with incident light, the sample comprising a photonic resonator device and one or more biomolecules coupled thereto, wherein the photonic resonator device is configured with one or more first resonances; directing the scattered photons from the sample to an interferometer, the interferometer having a first optical path and a second optical path; receiving, by at least one photo-detector, the scattered photons output from the first optical path and the second optical path; generating a power spectrum based on the received scattered photons, the power spectrum indicating temporal spectral fluctuations recorded by the at least one photo-detector based on the received scattered photons; and obtaining, based on correlation of the power spectrum, temporal dynamics of the temporal spectral fluctuations.
G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
G01N 21/49 - Scattering, i.e. diffuse reflection within a body or fluid
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
Methods and compositions for preventing activation of mutant TERT promoters are described, including for inhibiting cancer cells. In some cases, a GABPA-interacting domain or GABPB-interacting domain is linked to a ubiquitin ligase to prevent activation of mutant TERT promoters by a GABP complex.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
85.
GIANT MAGNETOELASTICITY ENABLED SELF-POWERED PRESSURE SENSOR FOR BIOMONITORING
The present embodiments relate generally to a soft system for producing a giant magnetoelastic effect. In some embodiments, the soft system is composed of platinum-catalyzed silicone polymer matrix and neodymium-iron-boron nanomagnets. The soft system shows up to four times more enhancement of the magnetomechanical coupling factor (T/Pa) than traditional rigid counterparts owing to a distinct physical mechanism. In embodiments, the giant magnetoelastic effect is coupled with magnetic induction to implement a soft magnetoelastic generator (MEG) as an approach to biomechanical energy conversion, a technology that was heretofore conventionally challenged by low current, high internal impedance, and low water/humidity resistance for decent operation stability. This new method of biomechanical-to-electrical conversion is intrinsically waterproof since the magnetic fields are able to penetrate water with negligible intensity loss. Thus, it was demonstrated to work stably on wet skin or in body fluids without any encapsulation, opening up alternative avenues for practical human-body centered energy, sensing, and therapeutic applications.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A multimodal biometric device is disclosed. An apparatus may include a non-contact imaging system. The non-contact imaging system may include imaging optics, optical illumination optically coupled to the imaging optics, and a configurable body part support to support different body parts at corresponding focal lengths to capture different portions of the different body parts. An apparatus may also include a housing coupled to the imaging optics, the optical illumination, and the configurable body part support.
Provided herein are compositions, systems, and methods to provide two gene editing-based approaches that can be used to correct the CD35 SCID-causing C202T mutation (TGA→CGA). In certain embodiments one approach involves CRISPR/Cas9 homology-directed repair (HDR)-mediated correction with a single-strand oligodeoxynucleotide (ssODN) homologous donor. In certain embodiments another approach comprises Adenine Base Editing (ABE)-correction, to precisely revert the CD35 SCID-causing C202T mutation (TGA→CGA).
Phase-based optoretinography (ORG) is performed using tissue velocity obtained from a modified optical coherence tomography (OCT) system. A swept-source generated OCT A-scan is used to assemble a 2-dimensional profile of the retinal tissue (B-scan) by laterally scanning the imaging beam. These B-scans can be taken at multiple time-points and assembled into a M-scan, which displays motion of a particular cross-section of retinal tissue (after correction for bulk motion). The method captures the changes between each timestep of the M-scan to deduce tissue velocities of the COST, ROST, and IS/OS, among others. An initial contraction of outer segments is detected in outer segments, followed by an elongation shortly thereafter. The tissue velocity measurements can be used to infer retinal dysfunction without the need for costly and computationally expensive scans using adaptive optics.
Seattle Children's Hospital DBA Seattle Children's Research Institute (USA)
Inventor
Chen, Yvonne Y.
Zah, Eugenia
Jensen, Michael C.
Abstract
A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (United Kingdom)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Li, Gang
Zanto, Theodore
Abstract
A signal generator is provided that is configured to generate a signal adapted to be delivered to the brain of a subject to alleviate nausea in the subject. The stimulation signal is defined by a waveform having a frequency and a phase. The stimulation signal is characterized by one or more instantaneous disruptions of the phase of the waveform. A system (100) for alleviating nausea is provided. The system (100) comprises: the signal generator (102) configured to generate the stimulation signal; and one or more electrodes (104, 106a-c) configured to deliver the stimulation signal to the brain of a subject.
Disclosed herein a polypeptides for use in chimeric antigen receptors (CARs) for binding to CD70-expressing cells. The polypeptides are variants of a natural ligand for CD70. CD70-targeting CARs demonstrate enhanced cytotoxic against CD70-positive cancer cells. The polypeptides may also be used to detect the presence of CD70-expressing cells that are implicated in disease.
95.
AMPHIPHILIC NANOPARTICLES TO TARGET AMYLOID FI-INDUCED MICROGLIAL ACTIVATION
Nanoparticle compositions and methods inhibiting amyloid beta (Aβ) fibrilization in a subject in need thereof using nanoparticles to target fibril β-amyloid (fAβ)-specific scavenger receptors. Also provided is a method of using nanoparticle compositions to treat Alzheimer's disease (AD) and similar amyloidopathies.
A heterogeneous photonic integrated circuit (PIC) comprising at least one hybrid Quantum Dot (QD) optical gain device is described. The PIC includes a silicon device layer and a silicon waveguide defined in the silicon device layer that includes a first tapered structure. The PIC further includes a III-V multilayer stack bonded to the Si device layer that includes a second tapered structure that corresponds to the first tapered structure to form a hybrid optical waveguide centered around an active region of the QD laser. A method of producing the described heterogeneous photonic integrated circuit is also described, which involves bonding a III-V substrate containing QD layers to a host SOI substrate with a top Si device layer.
H01S 5/22 - Structure or shape of the semiconductor body to guide the optical wave having a ridge or a stripe structure
H01S 3/063 - Waveguide lasers, e.g. laser amplifiers
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02F 1/11 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on acousto-optical elements, e.g. using variable diffraction by sound or like mechanical waves
97.
AN OLIGONUCLEOTIDE-BASED STRATEGY FOR CAPTURE, DETECTION, ADAPTATION, AND SEQUENCING OF TRNA USING NANOPORE TECHNOLOGY
Disclosed are methods of preparing a sequencing library to quantify tRNA abundance and tRNA modifications in an RNA sample that comprises contacting RNA with oligonucleotides in the presence of a ligating agent and performing nanopore direct sequencing. It also discloses a kit to perform said method.
98.
TUMOR EXTRACELLULAR VESICLE-BASED PROTEASE ACTIVITY ASSAY FOR DISEASE DETECTION AND TREATMENT MONITORING
A method of assaying for activity of a protease enzyme corresponding to a disease in a subject includes selectively capturing an extracellular vesicle (EV) from a sample from the subject; contacting the EV after the capturing with a probe molecule, the probe molecule including a peptide, a fluorescent moiety on a first end of the peptide and a quenching moiety on a second end of the peptide to provide a Fluorescence Resonance Energy Transfer (FRET) pair separated by the peptide, the peptide containing a cleavage sequence for the protease enzyme; and measuring a fluorescence of at least the fluorescent moiety after the contacting to indicate a presence or absence of the occurrence of cleavage of the peptide by the protease enzyme.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
Provided herein are genetically modified T cells that exhibit reduced T cell exhaustion upon repeated exposure to tumor cells compared to wild type T cells; and method of generating such T cells and using them for the treatment of cancer.
Disclosed herein are monospecific and bispecific antibodies that comprise a ALPPL2/ALPP-binding variable region. The bi-specific antibody is comprises of a monoclonal antibody targeting a tumor-specific cell surface antigen (ALPPL2/ALPP) with exquisite tissue specificity and a monoclonal antibody targeting a cell surface molecule (e.g., CD3) expressed by immune effector cells.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
